Rhythm Pharmaceuticals announced positive interim data from a Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS), showing meaningful reductions in BMI, fat mass, hyperphagia, and anxiety after six months of treatment. The trial involved 17 patients and demonstrated preservation of lean mass alongside improvements in food-related behaviors. These results support advancing setmelanotide to Phase 3 trials, offering hope for a rare disease with limited treatment options. Rhythm will discuss these findings in a conference call on June 13, 2026.
The FREELANDER 8 made its first public appearance at the Abu Dhabi Investment Forum in Shanghai on June 11, 2026, signaling its upcoming official launch in Abu Dhabi. This luxury electric SUV brand is a collaboration between Jaguar Land Rover and Che...
FREELANDER 8 made its first public appearance at the Abu Dhabi Investment Forum in Shanghai on June 11, 2026, ahead of its official launch in Abu Dhabi. The vehicle is a premium new energy SUV co-created by Jaguar Land Rover and Chery, combining Brit...
Johnson & Johnson announced that the Phase 3 MonumenTAL-3 study demonstrated that TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, significantly improved progression-free survival (up to 81.3%) and overall survival (up to...
Nebius reported a strong Q1 2026 with revenue increasing 6.8 times to $399 million, primarily fueled by its AI Cloud business which now accounts for about 98% of total revenue. The company sees strong demand momentum, highlighted by a record sales pi...
This week, retail investors showed strong interest in five stocks: SpaceX, Micron Technology, Advanced Micro Devices (AMD), Uber Technologies, and Super Micro Computer. SpaceX shares surged after its IPO, closing 19.3% higher on the first day. Micron...
